<it>In vivo </it>mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by <it>Streptococcus gordonii</it>
Tagliabue Aldo, Medaglini Donata, Xu Li and 8 more
BMC Biotechnology · 2003
doi:10.1186/1472-6750-3-15 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Background</p> <p>Interleukin-1 (IL-1) is a cytokine involved in the initiation and amplification of the defence response in infectious and inflammatory diseases. IL-1 receptor antagonist (IL-1ra) is an inactive member of the IL-1 family and represents one of the most potent mechanisms for controlling IL-1-dependent inflammation. IL-1ra has proven effective in the therapy of acute and chronic inflammatory diseases in experimental animal models and also in preliminary clinical trials. However, optimisation of therapeutic schedules is still needed. For instance, the use of drug delivery systems targeting specific mucosal sites may be useful to improve topical bioavailability and avoid side effects associated with systemic administration.</p> <p>Results</p> <p>In order to develop systems for the delivery of IL-1ra to mucosal target sites, a <it>Streptococcus gordonii </it>strain secreting human IL-1ra was constructed. The recombinant IL-1ra produced by <it>S. gordonii </it>was composed of the four amino acid residues RVFP of the fusion partner at the N-terminus, followed by the mature human IL-1ra protein. RFVP/IL-1ra displayed full biological activity <it>in vitro </it>in assays of inhibition of IL-1β-induced lymphocyte proliferation and was released by recombinant <it>S. gordonii in vivo </it>both at the vaginal and the gastrointestinal mucosa of mice. RFVP/IL-1ra appeared beneficial in the model of ulcerative colitis represented by IL-2<sup>-/- </sup>mice (knock-out for the interleukin-2 gene), as shown by the body weight increase of IL-2<sup>-/- </sup>mice locally treated with <it>S. gordonii </it>producing RFVP/IL-1ra.</p> <p>Conclusions</p> <p>These results indicate that recombinant <it>S. gordonii </it>can be successfully used as a delivery system for the selective targeting of mucosal surfaces with therapeutic proteins.</p>
Abstract licence: CC BY-NC-ND
Cited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.